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Edited by Veli-Pekka LehtoAbstract We addressed the issue of whether enhanced glycoly-
sis caused by mtDNA mutations independently induces metasta-
sis in tumor cells using mtDNA transfer technology. The
resultant trans-mitochondrial cybrids sharing the same nuclear
background of poorly metastatic carcinoma P29 cells,
P29mtA11 and P29mtD cybrids, possessed mtDNA with a
G13997A mutation from highly metastatic carcinoma A11 cells
and mtDNA with a 4696 bp deletion mutation, respectively. The
P29mtD cybrids expressed enhanced glycolysis, but did not ex-
press ROS overproduction and high metastatic potential,
whereas P29mtA11 cybrids showed enhanced glycolysis, ROS
overproduction, and high metastatic potential. Thus, enhanced
glycolysis alone does not induce metastasis in the cybrids.
 2008 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
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Involvement of mtDNA mutations and the resultant mito-
chondrial respiration defects in tumor development have been
suggested based on the evidence that most chemical carcino-
gens bind preferentially to mtDNA rather than to nuclear
DNA [1–3]. Moreover, somatic mutations in mtDNA are
accumulated preferentially in tumor cells rather than in normal
cells of the same subjects [4,5], and many subsequent studies
supported high frequencies of homoplasmic mutations in
mtDNA of tumors [6–9].
On the contrary, our previous studies showed that mtDNA
mutations were not involved in tumor development of cultured
mouse [10,11] and human cells [12,13] using trans-mitochon-
drial cybrids obtained by mtDNA transfer between normal
and tumor cells. The possibility that these observations repre-
sent some speciﬁc tumor cases can be excluded, since there has*Corresponding author. Fax: +81 298 53 6614.
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doi:10.1016/j.febslet.2008.09.024been no statistical evidence for the association of pathogenic
mtDNA mutations and tumor development in the patients
with mitochondrial diseases expressing respiration defects
due to the pathogenic mtDNA mutations. The possibility of
the involvement of polymorphic mtDNA mutations in tumor
development also can be excluded, since there has been no sta-
tistical evidence for the presence of maternal inheritance of tu-
mor development in spite of the strictly maternal inheritance of
mammalian mtDNA [14,15].
However, it is still possible that mtDNA mutations are in-
volved in other processes besides the oncogenic transformation
of normal cells to develop tumors, such as the malignant pro-
gression of tumor cells to develop metastatic potential. Our re-
cent study addressed this issue by means of mtDNA exchange
technology, and demonstrated that mtDNA mutations induc-
ing complex I defects and resultant overproduction of reactive
oxygen species (ROS) reversibly controlled malignant progres-
sion of tumor cells to develop metastatic potential [16]. How-
ever, considering that complex I defects simultaneously induce
enhanced glycolysis under normoxia (the Warburg eﬀect) and
ROS overproduction, it is necessary to determine whether the
Warburg eﬀect also controls metastasis independently. In fact,
recent reports demonstrated that up-regulation of glycolysis
caused by mutations or epigenetic controls of nuclear-coded
genes regulate tumor phenotypes by the induction of a pseu-
do-hypoxic pathway under normoxia [17–20].
To address this issue, we generated trans-mitochondrial
P29mtD cybrids by introduction of DmtDNA4696 with a
4696 bp deletion mutation into low metastatic Lewis lung car-
cinoma P29 cells. The P29mtD cybrids expressed mitochon-
drial respiration defects and enhanced glycolysis under
normoxia, but did not express ROS overproduction, providing
proper cellular system to examine whether the Warburg eﬀect
alone can control metastasis.2. Materials and Methods
2.1. Cell lines and cell culture
The mouse cell lines and their characteristics are listed in Table 1.
The P29 cells originated from Lewis lung carcinoma (C57BL/6 mouse
strain), and B82 cells are ﬁbrosarcoma cells derived from the L929
ﬁbroblast cell line (C3H/An mouse strain). Parental cells, q0 cells,
and the trans-mitochondrial cybrids were grown in normal medium
[DMEM + pyruvate (0.1 mg/ml) + uridine (50 mg/ml) + 10% fetal bo-
vine serum].blished by Elsevier B.V. All rights reserved.
Table 1
Genetic characteristics of parent cells and their trans-mitochondrial cybrids
Cell linesa Nuclear genotypes (genetic marker)b mtDNAgenotypes Fusion combination Selection
Nuclear donors · mtDNA donors
Nuclear donors
q0P29 P29 (HATr, BrdUs) mtDNA-less
mtDNA donors
B82mtP29 B82 (HATs, BrdUr) Wild type q0B82 · encP29 BrdU + UP-
B82mtA11 B82 (HATs, BrdUr) G13997A q0B82 · enA11 BrdU + UP-
B82mtD B82 (HATs, BrdUr) DmtDNA4696 q0B82 · platelets UP-
Trans-mitochondrial cybrids
P29mtP29 P29 (HATr, BrdUs) Wild type q0P29 · enB82mtP29 HAT + UP-
P29mtA11 P29 (HATr, BrdUs) G13997A q0P29 · enB82mtA11 HAT + UP-
P29mtD P29 (HATr, BrdUs) DmtDNA4696 q0P29 · enB82mtD HAT + UP-
aAs mtDNA donors, we used B82mtP29, B82mtA11, and B82mtD cybrids shearing the same nuclear background of B82 cells for excluding variations
of nuclear-coded cytoplasmic factors in mtDNA donors. B82mtP29 cybrids carrying nuclear DNA from B82 cells and mtDNA from P29 cells were
obtained by fusion of q0B82 cells with enucleated P29 cells and subsequent cultivation in the selection medium with BrdU and UP–. q0B82 cells can
survive in the selection medium with BrdU due to their lacking thimidine kinase activity, and cannot survive in the selection medium without uridine
and pyruvate (UP- medium) due to their lacking mtDNA. Thus, BrdU and UP- eliminate unenucleated P29 cells and unfused q0B82 cells,
respectively, and allow exclusive growth of the B82mtP29 cybrids. B82mtD cybrids carrying nuclear DNA from B82 cells and DmtDNA4696 were
obtained by fusion of q0B82 cells with platelets from mito-mice carrying DmtDNA4696 [23] in the UP– selection medium. As G13997A mtDNA
donors, we used B82mtA11 cybrids obtained in our previous work [16].
bAll the mtDNA donors sharing the B82 nuclear background lacking thymidine kinase activity cannot survive in the presence of a hypoxanthine/
aminopterin/thymidine (HAT). On the contrary, nuclear donors q0P29 cells can grow in the HAT selection medium due to their processing thimidine
kinase activity, but not in UP– selection medium due to their complete respiration defects by mtDNA depletion. Thus, HAT and UP– allow exclusive
growth of the P29mtP29, P29mtA11, and P29mtD cybrids.
cen Represents enucleated.
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We isolated q0 cells by treating parental cells with 1.5 mg/ml diterca-
linium (DC), an antitumor bis-intercalating agent [21]. Complete
depletion of mtDNA was conﬁrmed by PCR analysis. Enucleated cells
of the mtDNA donor were prepared by their pretreatment with cyto-
chalasin B (10 lg/ml) for 10 min and centrifugation at 12000 · g for
30 min. Resultant cytoplasts were fused with q0 cells by polyethylene
glycol. Trans-mitochondrial cybrids were isolated in the selection med-
ium that allows exclusive growth of the cybrids (see Table 1).
2.3. Genotyping of mtDNAs
Transfer of mtDNAs in the cybrids was conﬁrmed by RFLP analysis
of the PCR products and Southern blot analysis. For recognition of
the G13997A mutation, a 147-bp fragment containing the 13997 site
was ampliﬁed by PCR. The nucleotide sequences from n.p. 13963 to
13996 (CCCACTAACAATTAAACCTAAACCTCCATActTA, small
letters indicate the mismatch site) and n.p. 14109 to 14076
(TTCATGTCATTGGTCGCAGTTGAATGCTGTGTAG) were used
as oligonucleotide primers. Combination of the PCR-generated muta-
tion with the G13997A mutation creates a restriction site for Aﬂ II,
and generates 114-bp and 33-bp fragments on Aﬂ II digestion. The
restriction fragments were separated in 3% agarose gel. To estimate
the proportion of DmtDNA, we carried out Southern blot analysis. To-
talDNAs (3 lg) extracted from cybridswere digestedwith the restriction
enzymeXho I. Restriction fragments were separated in 0.8% agarose gel,
transferred to a nylonmembrane, andhybridizedwith alkaline phospha-
tase-labeledmousemtDNAprobes (n.p. 1751–3803). Probe labeling and
signal detectionwere carried out as described in the protocols of theAlk-
Phos Direct (GE Healthcare, Buckinghamshire, UK). For quantiﬁca-
tion of DmtDNA, we use the NIH IMAGE program.
2.4. Biochemical measurement of respiratory enzyme activities
Cells in log-phase growth were harvested, and the respiratory com-
plexes were assayed as described before [22]. Brieﬂy, NADH and cyto-
chrome c (oxidized form) were used as substrates for estimation of
complexes I + III activity, and the reduction of cytochrome c was mon-
itored at 550 nm. For estimation of complexes II + III activity, sodium
succinate and cytochrome c (oxidized form) were used as substrates,
and reduction of cytochrome c was monitored at 550 nm. For estima-
tion of complex IV activity, cytochrome c (reduced form) was used as
substrates, and the enzyme activity was determined by monitoring the
oxidation of cytochrome c at 550 nm.2.5. Measurement of ROS production
ROS generation was detected with mitochondrial superoxide
indicator MitoSOX-RED (Invitrogen, Carlsbad, CA, USA). Cells
were incubated with 5 lM MitoSOX-RED for 10 min at 37 C in
serum-free DMEM, washed twice with Dulbeccos phosphate-buﬀered
saline (DPBS), and then immediately analyzed with a FACS can ﬂow
cytometer (Becton Dickinson, Mountain View, CA, USA).2.6. SDS–PAGE and Western blotting
To detect MCL-1, cells were lysed on ice for 10 min in 1% Triton
X-100, 1% sodium deoxycholate, 0.1% SDS, 50 mM Tris–HCl (pH
7.5), 150 mM NaCl, 1 mM PMSF, and protease inhibitor cocktail
(Sigma–Aldrich, St. Louis, MO, USA). After centrifugation at
10000 · g for 10 min at 4 C, the supernatant was used as a sample.
Proteins were resolved by SDS–PAGE under reducing conditions.
The resolved proteins were transferred electrophoretically to a nitro-
cellulose membrane. After incubation with 5% dry milk in TBS-T
[150 mM NaCl, 50 mM Tris–HCl (pH 7.4), 0.05% Tween 20] for at
least 1 h at room temperature, the membrane was incubated with
polyclonal anti-MCL-1 antibody (Santa Cruz Biotechnologies, Inc.,
Santa Cruz, CA, USA) for 1 h at room temperature, washed exten-
sively with TBS-T, and then incubated with horseradish peroxidase-
conjugated goat anti-rabbit IgG. Proteins were detected using ECL
Western blotting detection reagents (GE Healthcare). For loading
controls, the membrane was stripped, and subsequently incubated
with monoclonal anti-b-actin antibody (Sigma–Aldrich) followed by
incubation with horseradish peroxidase-conjugated goat anti-mouse
IgG.
2.7. Measurement of the concentration of lactate in the cell medium
Cells were seeded at 5 · 104 cells/well of a 6-well plate and cultured
for 24 h. The amounts of lactate in the cell medium were estimated
using an F-kit L-Lactic acid (Roche, Basel, Switzerland).2.8. Assays of metastatic potential
To test experimental metastatic potential, 5 · 105 cells/100 ll PBS
were injected into the tail vein of 6-week-old male C57BL/6 mice
(CLEA Japan, Tokyo, Japan). The mice were sacriﬁced 18 days later,
and their lungs were removed. The lungs were ﬁxed in the Bouins solu-
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3.1. Isolation of the mtDNA donors sharing the same nuclear
background of B82 cells
This study examined whether the Warburg eﬀect induced by
mitochondrial respiration defects alone controls metastasis in
mouse Lewis lung carcinoma cells. For this, we used mtDNA-
less (q0) P29 cells derived from poorly metastatic Lewis lung
carcinoma P29 cells as nuclear DNA donors andmtDNA recip-
ients (Table 1).
As mtDNA donors, we isolated trans-mitochondrial
B82mtP29, B82mtA11, and B82mtD cybrids shearing the same
nuclear background of B82 cells (Table 1). The B82mtP29 cy-
brids carrying nuclear DNA from B82 cells and mtDNA from
P29 cells were obtained by fusion of q0B82 cells with enucle-
ated P29 cells (Table 1). The B82mtD cybrids carrying nuclear
DNA of B82 cells and DmtDNA4696 were obtained by fusion
of q0B82 cells with platelets from mito-mice carrying
DmtDNA4696 [23]. The B82mtA11 cybrids isolated in our pre-
vious work [16] were obtained by fusion of q0B82 cells with
enucleated A11 cells.
These cybrids are appropriate to be used as mtDNA donors
to q0P29 cells by the following two reasons. One is that the cy-
brids sharing the B82 nuclear background can exclude the
inﬂuence of variations of the nuclear-coded cytoplasmic fac-
tors on metastasis of the mtDNA recipient q0P29 cells. An-
other is that the cybrids sharing B82 nuclear background
lack thymidine kinase activity, and cannot survive in the pres-
ence of a hypoxanthine/aminopterin/thymidine (HAT). Thus,
unenucleated mtDNA donor cybrids can be excluded in the














Fig. 1. Genotyping of mtDNA and respiratory complex activities. (A)
Identiﬁcation of the mtDNA genotypes. Upper panel: For identiﬁca-
tion of A11 mtDNA with the G13997A mutation, the PCR products
were digested with Aﬂ II. The PCR products of the mtDNA with the
G13997A mutation from A11 cells produce 114- and 33-bp fragments
because of the gain of an Aﬂ II site by a G13997A substitution,
whereas those of mtDNA without the mutation produce a 147-bp
fragment due to the absence of the Aﬂ II site. Lower panel: For
estimation of DmtDNA4696 proportions in the cybrids, we used
Southern blot analysis of total DNA digested with the restriction
endonuclease Xho I. Fragments of 16.3 kbp and 11.6 kbp correspond
to wild-type mtDNA and DmtDNA4696, respectively. (B) Biochemical
analysis of respiratory complex activities. Respiratory complex I
(NADH dehydrogenase), complex II (succinate dehydrogenase), com-
plex III (cytochrome c reductase), and complex IV (cytochrome c
oxidase) are components of electron-transport chain, and are located
in the mitochondrial inner membrane. Mitochondrial respiratory
function was examined by estimating their activities. Since the activity
of complexes II + III is normal in the P29mtA11 cybrids, reduced
activity of complexes I + III in them should result from complex I
defects. Bars represent the means ± S.D. (n = 3). *, P < 0.05.3.2. Isolation of trans-mitochondrial cybrids carrying mtDNA
with pathogenic mutation
These mtDNA donor cybrids were used for obtaining the
trans-mitochondrial cybrids, P29mtP29, P29mtA11, and
P29mtD (Table 1). First, we isolated trans-mitochondrial
P29mtD cybrids, possessing the nuclear genome of the P29 cells
and mitochondrial genome of DmtDNA4696 with a 4696 bp
deletion mutation, by the fusion of the q0P29 cells with enucle-
ated B82mtD cybrids (Table 1). Our previous reports showed
that accumulation of the DmtDNA4696 induced suppression
of overall mitochondrial translation due to the large-scale dele-
tion mutation including ﬁve mitochondrial tRNA genes from
DmtDNA4696 [23,24]. Therefore, we expected that the
P29mtD cybrids with DmtDNA4696 would express enhanced
glycolysis under normoxia, but not express ROS overproduc-
tion, probably due to overall mitochondrial respiration defects
induced by DmtDNA4696. Thus, the P29mtD cybrids would
provide an ideal system to examine whether enhanced glycoly-
sis alone could induce metastasis in poorly metastatic P29 cells.
We also obtained trans-mitochondrial P29mtA11 and
P29mt29 cybrids by the fusion of the q0P29 cells with enucle-
ated B82mtA11 and B82mtP29 cybrids for using as positive
and negative controls of metastasis, respectively (Table 1).
Our recent report [16] isolated P29mtA11 and P29mtP29 cy-
brids by the fusion of q0P29 with enucleated A11 cells and
P29 cells, respectively, and showed that the P29mtA11 cybrids
were highly metastatic and P29mt29 cybrids were poorly met-
astatic. However, it was possible that some cytoplasmic factors
encoded by nuclear DNA may aﬀect metastatic potentials,since nuclear background of mtDNA donor A11 and P29 cells
are diﬀerent from each other. This study can exclude this pos-
sibility by the use of the B82mtA11 and B82mtP29 cybrids
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donors.
3.3. mtDNA genotypes and resultant phenotypes of respiratory
function in the cybrids
Using PCR and Southern blot analyses, we carried out the
mtDNA genotyping of the P29mtP29, P29mtA11, and
P29mtD cybrids (Fig. 1A). The G13997A mutation in mtDNA
from A11 cells creates an Aﬂ II site in PCR products ampliﬁed
using mismatch primers [16]. Therefore, we carried out Aﬂ II
digestion of their PCR products, and showed that mtDNA
in P29mtA11 cybrids possessed a homoplasmic G13997A
mutation, while mtDNA in P29mtP29 and P29mtD cybrids
did not (Fig. 1A, upper panel). The DmtDNA4696 was identi-
ﬁed by Southern blot analysis. The results showed that
P29mtD cybrids possessed 88% DmtDNA4696, while the
P29mtP29 and P29mtA11 cybrids did not have any
DmtDNA4696 (Fig. 1A, lower panel). As expected, no
mtDNA was found in parental q0P29 cells (Fig. 1A).
Then, their mitochondrial respiratory function was exam-
ined by estimating activities of mitochondrial respiratory com-
plexes (Fig. 1B). Parental q0P29 cells and P29mtD cybrids
showed overall respiration defects due to complete mtDNA
depletion and accumulation of DmtDNA4696 possessing a
4696 bp-deletion mutation, respectively. Speciﬁc reduction of
complex I activity was exclusively observed in P29mtA11 cy-
brids, while P29mtP29 cybrids showed normal mitochondrial
respiratory function (Fig. 1B).
3.4. Eﬀects of respiration defects on ROS production and
nuclear-coded MCL-1 expression
Since we have reported recently [16] that ROS overproduc-
tion and resultant up-regulation of nuclear-coded antiapopto-
tic MCL-1 (myeloid cell leukemia-1), at least in part, are
























Fig. 2. Eﬀects of mitochondrial respiratory function on ROS production and
ﬂow-cytometric analysis using 1 · 106 cells. Cells treated with 5 lM MitoS
superoxide. (B) Expression of nuclear-coded MCL-1 by Western blot analysand the nuclear-coded MCL-1 in the cybrids (Fig. 2). The
P29mtD cybrids did not show ROS overproduction (Fig. 2A)
and up-regulation of MCL-1 (Fig. 2B). Similar results were ob-
tained in q0P29 cells and the P29mtP29 cybrids (Fig. 2B). On
the contrary, the P29mtA11 cybrids expressing complex I de-
fects showed ROS overproduction (Fig. 2A) and upregulation
of MCL-1 (Fig. 2B). These observations suggest that ROS
overproduction and up-regulation of MCL-1 cannot be in-
duced by overall mitochondrial respiration defects or normal
respiratory function.
3.5. Eﬀects of mitochondrial respiration defects on glycolytic
activity and metastasis
Then, we examined the glycolytic activity of these cybrids
and parental q0P29 cells by estimating lactate level in their cul-
ture medium. As expected, parental q0P29 cells and P29mtD
cybrids expressing overall respiration defects (Fig. 1B) showed
signiﬁcant overproduction of lactate (Fig. 3A). Slight overpro-
duction of lactate was observed in P29mtA11 cybrids express-
ing complex I defects, while P29mtP29 cybrids showed normal
lactate secretion (Fig. 3A). These observations suggest that
q0P29 cells and P29mtD cybrids expressed enhanced glycolysis
under normoxia, i.e., the Warburg eﬀect, due to overall mito-
chondrial respiration defects, but did not express ROS over-
production. Thus, they can be used for determination of
whether the Warburg eﬀect alone induces high metastatic po-
tential in tumor cells.
Finally, we examined metastatic potentials by inoculation of
the cybrids into the tail vein of male C57BL/6 mice and count-
ing the number of nodules formed in the lung 18 days after
inoculation. The q0P29 cells and P29mtD cybrids expressing
the Warburg eﬀect, but not expressing ROS overproduction
did not form lung nodules (Fig. 3B). As expected from our re-
cent report [16], P29mtA11 cybrids expressing the Warburg ef-
fect and ROS overproduction formed nodules in the lung,P29mtΔ ρ0P29
-Red
MCL-l expression. (A) Estimation of ROS production. We carried out
OX-RED were subjected to FACScan for quantitative estimation of
























































Fig. 3. Eﬀects of the enhanced lactate production on expression of
metastatic potential. (A) The lactate level in culture medium. The
P29mtP29 cybrids and q0P29 cells were used as cells with normal
mitochondrial respiratory function and without mitochondrial respi-
ratory function, respectively. Bars represent the means ± S.D. (n = 3).
*, P < 0.05; **, P < 0.005. (B) Experimental metastatic potential. We
counted number of nodules formed in the lung after inoculation of the
cybrids into the tail vein. Enhanced glycolysis is not necessarily
correlated with expression of high metastatic potential. Bars represent
the means ± S.D. (n = 6).
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tion did not form lung nodules (Fig. 3B). These observations
suggest that the mtDNA mutations that induce ROS overpro-
duction can be responsible for metastasis, but the mtDNA
mutation or mtDNA depletion that induces the Warburg eﬀect
alone are not responsible for metastasis at least in Lewis lung
carcinoma cell lines.4. Discussion
Our recent report demonstrated that complex I defects
caused by the mtDNA mutations and resultant ROS overpro-
duction reversibly control metastasis, and that ROS overpro-
duction controls metastasis not by induction of genetic
instability or by upregulation of glycolysis, but by upregula-
tion of metastasis-related nuclear genes [16]. However, since
complex I defects simultaneously induce up-regulation of gly-
colysis in addition to ROS overproduction, it is still possible
that upregulation of glycolysis caused by complex I defects
alone can be responsible for metastasis. We examined this pos-
sibility by isolation of the P29mtD cybrids that expressed en-
hanced glycolysis, but did not express ROS overproduction
(Fig. 2), and showed that metastasis was not induced in the
P29mtD cybrids (Fig. 3). Since enhanced glycolysis under nor-
moxia, i.e., the Warburg eﬀect, caused by mitochondrial respi-
ration defects alone did not induce metastasis in the P29mtD
cybrids, the induction of high metastatic potential in the
P29mtA11 cybrids [16] would be due to ROS overproduction,
but not to the Warburg eﬀect caused by complex I defects.The remaining question is whether enhanced glycolysis may
induce oncogenic transformation of normal cells to develop tu-
mors, even though it did not induce malignant progression of
tumor cells to develop metastasis (Fig. 3B). This possibility
would be excluded, since mito-mice expressing enhanced gly-
colysis due to accumulation DmtDNA4696 [23,24] did not
show any bias to form tumors in their tissues (Ishikawa et al.,
unpublished observations). Thus, enhanced glycolysis induced
by mitochondrial respiration defects would not be involved in
both tumor and metastasis development at least in tissues of
mito-mice and in mouse tumor cells used in this study. To pro-
vide direct evidence of whether the Warburg eﬀect induced by
mitochondrial respiration defects is not involved in tumor
development, we are going to isolate embryonic ﬁbroblast cell
lines possessing DmtDNA4696 from the mito-mice, and exam-
ine whether they are prone to develop tumors.
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